Company Management, Scientific and Advisory Boards

Liver Cancer publications

Garin, E., Rolland, Y., Laffont, S., & Edeline, J. (2016). Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 43(3), 559–575. https://doi.org/10.1007/s00259-015-3157-8
Palard, X., Edeline, J., Rolland, Y., Le Sourd, S., Pracht, M., Laffont, S., … Garin, E. (2018). Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 45(3), 392–401. https://doi.org/10.1007/s00259-017-3845-7
Raoul, J.-L., Boucher, E., Rolland, Y., & Garin, E. (2010). Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nature Reviews Gastroenterology & Hepatology, 7(1), 41–49. https://doi.org/10.1038/nrgastro.2009.202
Le Dortz, L., De Guibert, S., Bayat, S., Devillers, A., Houot, R., Rolland, Y., … Garin, E. (2010). Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 37(12), 2307–2314. https://doi.org/10.1007/s00259-010-1539-5
Garin, E., Rolland, Y., Boucher, E., Ardisson, V., Laffont, S., Boudjema, K., … Raoul, J.-L. (2010). First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. European Journal of Nuclear Medicine and Molecular Imaging, 37(3), 453–461. https://doi.org/10.1007/s00259-009-1279-6
Le Roux, P.-Y., Bouchet, F., Querellou, S., Vervueren, L., Lacoeuille, F., Turzo, A., … Couturier, O.-F. (2011). American consensus recommendations for gastric scintigraphy: curve fitting with only a few points remains an easy and accurate method to obtain reliable and reproducible gastric emptying estimates. Nuclear Medicine Communications, 32(1), 30–36. https://doi.org/10.1097/MNM.0b013e3283404270
Garin, E., Rolland, Y., Lenoir, L., Pracht, M., Mesbah, H., Porée, P., … Boucher, E. (2011). Utility of Quantitative 99m Tc-MAA SPECT/CT for 90 yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach. International Journal of Molecular Imaging, 2011, 1–8. https://doi.org/10.1155/2011/398051
Garin, E., Lenoir, L., Rolland, Y., Laffont, S., Pracht, M., Mesbah, H., … Boucher, E. (2011). Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nuclear Medicine Communications, 32(12), 1245–1255. https://doi.org/10.1097/MNM.0b013e32834a716b
Lenoir, L., Edeline, J., Rolland, Y., Pracht, M., Raoul, J.-L., Ardisson, V., … Garin, E. (2012). Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 39(5), 872–880. https://doi.org/10.1007/s00259-011-2033-4
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., … Raoul, J.-L. (2012). Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma: mRECIST Impact in Sorafenib-Treated HCC. Cancer, 118(1), 147–156. https://doi.org/10.1002/cncr.26255
Garin, E., Lenoir, L., Rolland, Y., Edeline, J., Mesbah, H., Laffont, S., … Boucher, E. (2012). Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results. Journal of Nuclear Medicine, 53(2), 255–263. https://doi.org/10.2967/jnumed.111.094235
Masserot-Lureau, C., Adoui, N., Degos, F., de Bazelaire, C., Soulier, J., Chevret, S., … Leblanc, T. (2012). Incidence of liver abnormalities in Fanconi anemia patients. American Journal of Hematology, 87(5), 547–549. https://doi.org/10.1002/ajh.23153
Boudjema, K., Sulpice, L., Garnier, S., Bretagne, J.-F., Gandon, Y., & Rohou, T. (2013). A Simple System to Predict Perihilar Cholangiocarcinoma Resectability. Journal of Gastrointestinal Surgery, 17(7), 1247–1256. https://doi.org/10.1007/s11605-013-2215-4
Fosse, P., Girault, S., Hoareau, J., Testard, A., Couturier, O., & Morel, O. (2013). Unusual Uptake of 18FDG by a Hepatic Adenoma: Clinical Nuclear Medicine, 38(2), 135–136. https://doi.org/10.1097/RLU.0b013e318279b95a
Carlier, T., Eugène, T., Bodet-Milin, C., Garin, E., Ansquer, C., Rousseau, C., … Kraeber-Bodéré, F. (2013). Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Research, 3(1), 11. https://doi.org/10.1186/2191-219X-3-11
Edeline, J., Du, F. L., Rayar, M., Rolland, Y., Beuzit, L., Boudjema, K., … Boucher, E. (2015). Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma: Clinical Nuclear Medicine, 40(11), 851–855. https://doi.org/10.1097/RLU.0000000000000904
Edeline, J., Crouzet, L., Campillo-Gimenez, B., Rolland, Y., Pracht, M., Guillygomarc’h, A., … Garin, E. (2016). Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. European Journal of Nuclear Medicine and Molecular Imaging, 43(4), 635–643. https://doi.org/10.1007/s00259-015-3210-7
Beuzit, L., Edeline, J., Brun, V., Ronot, M., Guillygomarc’h, A., Boudjema, K., … Rolland, Y. (2016). Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). European Journal of Radiology, 85(8), 1445–1452. https://doi.org/10.1016/j.ejrad.2016.05.020
Garin, E., Edeline, J., & Rolland, Y. (2016). High Impact of Preferential Flow on 99mTc-MAA and 90Y-Loaded Microsphere Uptake Correlation. Journal of Nuclear Medicine, 57(11), 1829–1830. https://doi.org/10.2967/jnumed.116.175943
Garin, E., Rolland, Y., Pracht, M., Le Sourd, S., Laffont, S., Mesbah, H., … Edeline, J. (2017). High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. Liver International, 37(1), 101–110. https://doi.org/10.1111/liv.13220
Vilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G.-P., … Marthey, L. (2017). Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology, 18(12), 1624–1636. https://doi.org/10.1016/S1470-2045(17)30683-6
Manceau, V., Palard, X., Rolland, Y., Pracht, M., Le Sourd, S., Laffont, S., … Garin, E. (2018). A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 45(10), 1731–1741. https://doi.org/10.1007/s00259-018-3990-7
Simoncini, C., Jurczuk, K., Reska, D., Esneault, S., Nunes, J.-C., Bellanger, J.-J., … Kretowski, M. (2018). Towards a patient-specific hepatic arterial modeling for microspheres distribution optimization in SIRT protocol. Medical & Biological Engineering & Computing, 56(3), 515–529. https://doi.org/10.1007/s11517-017-1703-1
Garin, E., Rolland, Y., Campillo-Gimenez, B., & Edeline, J. (2018). Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. The Lancet Oncology, 19(2), e70. https://doi.org/10.1016/S1470-2045(18)30024-X
Winter, K. S., Hofmann, F. O., Thierfelder, K. M., Holch, J. W., Hesse, N., Baumann, A. B., … D’Anastasi, M. (2018). Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. European Radiology, 28(11), 4839–4848. https://doi.org/10.1007/s00330-018-5424-0
Bourien, H., Palard, X., Rolland, Y., Le Du, F., Beuzit, L., Uguen, T., … Edeline, J. (2019). Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. European Journal of Nuclear Medicine and Molecular Imaging, 46(3), 669–676. https://doi.org/10.1007/s00259-018-4199-5
Delaunay, K., Edeline, J., Rolland, Y., Lepareur, N., Laffont, S., Palard, X., … Garin, E. (2019). Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 46(7), 1506–1517. https://doi.org/10.1007/s00259-019-04277-9
Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., … Garin, E. (2020). Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6(1), 51. https://doi.org/10.1001/jamaoncol.2019.3702
Garin, E., Rolland, Y., & Edeline, J. (2019). 90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry. Seminars in Nuclear Medicine, 49(3), 218–226. https://doi.org/10.1053/j.semnuclmed.2019.01.006